Related Experiment Video

Updated: May 16, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Autoantibodies are not associated with familial mediterranean fever

Emel Guler1, Ece Kaptanoglu, Ozlem Sahin

  • 1Kayseri Education and Research Hospital, Kayseri, Turkey.

Acta Reumatologica Portuguesa
|November 15, 2012
PubMed
Abstract

Insights

Autoantibody positivity in Familial Mediterranean fever (FMF) patients mirrors the general population, with no link found between MEFV gene mutations and autoantibody formation. This suggests FMF

Area of Science:

  • Rheumatology
  • Genetics
  • Immunology

Background:

  • Familial Mediterranean fever (FMF) is an autoinflammatory disease.
  • MEFV gene mutations are implicated in FMF pathogenesis.
  • The role of autoantibodies in FMF and their association with MEFV mutations is unclear.

Purpose of the Study:

  • To assess autoantibody prevalence in FMF patients.
  • To investigate the relationship between FMF clinical activity and autoantibody positivity.
  • To explore the association between MEFV gene mutations and autoantibody formation in FMF.

Main Methods:

  • Fifty FMF patients and 27 healthy controls were enrolled.
  • Autoantibody testing included antinuclear antibody (ANA), extractable nuclear antigen (ENA) profile, anti-cyclic citrullinated peptide (anti-CCP), and rheumatoid factor (RF).
  • MEFV gene mutations were identified in FMF patients.

Main Results:

  • No significant differences in ANA, ENA profile, anti-CCP, or RF positivity were observed between FMF patients and controls.
  • No correlation was found between autoantibody status and clinical manifestations in FMF patients.
  • MEFV gene mutations were present in 98% of FMF patients.

Conclusions:

  • Autoantibody positivity in FMF patients is comparable to the healthy population.
  • MEFV mutations do not appear to influence autoantibody formation in FMF.
  • Findings suggest distinct mechanisms underlying FMF compared to other autoantibody-mediated diseases.

More Related Videos

Anti-Nuclear Antibody Screening Using HEp-2 Cells13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...